SCLN Share Price

Open 9.80 Change Price %
High 9.90 1 Day -0.05 -0.51
Low 9.65 1 Week 0.10 1.04
Close 9.70 1 Month -0.05 -0.51
Volume 181630 1 Year -3.46 -26.29
52 Week High 15.02
52 Week Low 8.55
SCLN Important Levels
Resistance 2 9.93
Resistance 1 9.84
Pivot 9.75
Support 1 9.56
Support 2 9.47
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
AKRX 33.09 1.13%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
ACAS 17.99 0.39%
WRES 0.09 28.57%
More..
NASDAQ USA Top Gainers Stocks
PGRX 0.06 100.00%
SPIR 0.02 100.00%
LOCM 0.09 50.00%
RITT 0.03 50.00%
CLNT 4.50 30.81%
CALI 3.45 29.21%
WRES 0.09 28.57%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
ULTR 0.05 -37.50%
More..

SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN)

SCLN Technical Analysis 4
As on 25th Apr 2017 SCLN Share Price closed @ 9.70 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 10.64 & Sell for SHORT-TERM with Stoploss of 9.73 we also expect STOCK to react on Following IMPORTANT LEVELS.
SCLN Target for April
1st Target up-side 10.41
2nd Target up-side 10.84
3rd Target up-side 11.27
1st Target down-side 9.19
2nd Target down-side 8.76
3rd Target down-side 8.33
SCLN Other Details
Segment EQ
Market Capital 307798784.00
Sector Healthcare
Industry Drug Manufacturers - Other
Offical website http://www.sciclone.com
SCLN Address
SCLN
950 Tower Lane
Suite 900
Foster City, CA 94404
United States
Phone: 650-358-3456
Fax: 650-358-3469
SCLN Latest News
Interactive Technical Analysis Chart SciClone Pharmaceuticals, Inc. ( SCLN NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on SciClone Pharmaceuticals, Inc.
SCLN Business Profile
SciClone Pharmaceuticals, Inc. (SciClone) is a specialty pharmaceutical company. The Company has a product portfolio of therapies for oncology, infectious diseases, cardiovascular, urological, respiratory and central nervous system disorders. The Company�s main product is ZADAXIN (thymalfasin), which is approved in over 30 countries, which is used for the treatment of hepatitis B virus (HBV), hepatitis C (HCV), as a vaccine adjuvant, and certain cancers. In China, thymalfasin is also included in the treatment guidelines issued by the Ministry of Health for liver cancer. SciClone�s marketed portfolio also includes Depakine, the prescribed broad-spectrum anti-convulsant in China; Tritace, an ACE inhibitor for the treatment of hypertension; Stilnox, a hypnotic for the short-term treatment of insomnia (marketed as Ambien in the United States), and Aggrastat, an intervention cardiology product. On April 18, 2011, the Company acquired NovaMed Pharmaceuticals, Inc.